ストックスクリーナーアプリを入手
3.6955
1.51%
0.0555
前日終値:
$3.64
開ける：
$3.68
24時間の取引高:
7.12M
Relative Volume:
0.46
時価総額：
$1.52B
収益：
$263.44M
当期純損益:
$-390.98M
株価収益率:
-3.2966
EPS:
-1.121
ネットキャッシュフロー:
$-336.24M
1週間 パフォーマンス:
+6.48%
1か月 パフォーマンス:
-6.69%
6か月 パフォーマンス:
+64.96%
1年 パフォーマンス:
+14.40%
1日の値動き範囲:
$3.53
$3.71
1週間の範囲:
$3.42
$4.31
52週間の値動き範囲:
$1.6385
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
名前
Iovance Biotherapeutics Inc
セクター
電話
(650) 260-7120
住所
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.695 | 1.50B | 263.44M | -390.98M | -336.24M | -1.121 |
VRTX
Vertex Pharmaceuticals Inc
|
442.76 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.47 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
842.22 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
335.30 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
317.07 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | アップグレード | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | ダウングレード | Goldman | Neutral → Sell |
| 2025-05-16 | ダウングレード | UBS | Buy → Neutral |
| 2025-05-12 | ダウングレード | Truist | Buy → Hold |
| 2025-05-09 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-07-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-09-18 | 繰り返されました | Barclays | Overweight |
| 2023-05-30 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-27 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-08-18 | 再開されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Stifel | Hold → Buy |
| 2021-12-07 | 再開されました | Cowen | Outperform |
| 2021-06-10 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | ダウングレード | Stifel | Buy → Hold |
| 2021-05-03 | 開始されました | Truist | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2021-03-08 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 開始されました | Mizuho | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-04-29 | 開始されました | Piper Jaffray | Overweight |
| 2019-02-28 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-02-07 | 開始されました | Robert W. Baird | Outperform |
| 2018-12-31 | 再開されました | B. Riley FBR | Buy |
| 2018-07-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-04-10 | アップグレード | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 繰り返されました | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-01 | 繰り返されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Iovance Biotherapeutics Inc (IOVA) 最新ニュース
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN
IOVA Deadline: IOVA Investors Have Opportunity to Lead Iovance B - GuruFocus
Macro Review: Will Iovance Biotherapeutics Inc benefit from green energy policiesDividend Hike & Verified Chart Pattern Trade Signals - baoquankhu1.vn
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
IOVA stock slump takes Wall Street, retail by surprise — here’s why - MSN
Iovance Biotherapeutics: Analyzing Growth Potential and Risks After Amtagvi Approval - IndexBox
Iovance Biotherapeutics (IOVA) Is Up 16.9% After Stronger Real-World Amtagvi Data Spurs Franchise Hopes - Sahm
IOVA Maintained by Chardan Capital -- Price Target Stays at $16 - GuruFocus
IOVA Stock Grinds Sideways As Traders Weigh Heavy Losses - timothysykes.com
Iovance Biotherapeutics Faces Stock Decline Amid Market Dynamics - Intellectia AI
Jefferies reiterates Iovance Biotherapeutics stock rating at buy By Investing.com - Investing.com Canada
Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
IOVA: Analyst Comments on FDA Rejection Impact - GuruFocus
Iovance Biotherapeutics (IOVA) Maintains Strong Outlook Amid Reg - GuruFocus
Iovance Biotherapeutics Faces Market Waves Amid Losses and Strategic Moves - timothysykes.com
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? - Yahoo Finance
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? - The Motley Fool
IOVA Stock Holds Key Support As Biotech Traders Circle - StocksToTrade
IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Iovance’s Landmark FDA Approval Shakes Up Melanoma Treatment Market - StocksToTrade
A Look At Iovance Biotherapeutics (IOVA) Valuation After Strong Amtagvi Data And Growing Pipeline Momentum - Sahm
Analyst sentiment remains strong on Iovance Biotherapeutics (IOVA) amid US rollout of melanoma drug, Amtagvi - MSN
Aug Fed Impact: How correlated is Iovance Biotherapeutics Inc to the S P5002026 Top Gainers & Community Shared Stock Ideas - baoquankhu1.vn
Market Review: How correlated is Iovance Biotherapeutics Inc to the S P500Portfolio Performance Summary & Low Risk High Reward Ideas - baoquankhu1.vn
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Below 50 Day Moving AverageHere's What Happened - MarketBeat
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA) - Seeking Alpha
IOVA SEC FilingsIovance Biotherp 10-K, 10-Q, 8-K Forms - Stock Titan
Why Is Iovance Biotherapeutics, Inc. (IOVA) Stock Down Today? - Meyka
Iovance Biotherapeutics (IOVA) Is Down 6.5% After FDA Questions Amtagvi Marketing Claims Has The Bull Case Changed? - Sahm
Iovance Biotherapeutics Inc (IOVA) Stock Price, Quote, News & History - Benzinga
Why is Iovance Biotherapeutics Inc stock going up2026 Final Week & Real-Time Chart Breakout Alerts - baoquankhu1.vn
A Look At Iovance Biotherapeutics (IOVA) Valuation After FDA Concerns Over Amtagvi Marketing Practices - Sahm
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN
After IOVA stock’s best day in 2 years, analyst sees over 300% upside: Here’s why - MSN
Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help (NASDAQ:IOVA) - Seeking Alpha
Market Outlook: Is Iovance Biotherapeutics Inc a stock for growth or value investors2026 Buyback Activity & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Volume Recap: Is Iovance Biotherapeutics Inc still a buy after recent gains2026 Price Momentum & Growth Oriented Trading Recommendations - baoquankhu1.vn
IOVA | Iovance Biotherapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Iovance Biotherapeutics, Inc. $IOVA Stock Position Raised by Mirador Capital Partners LP - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Iovance Biotherapeutics (MIL:1IOVA) NonCurrent Deferred Rev - GuruFocus
Vanguard (IOVA) shows 0 shares after Jan 12, 2026 realignment - Stock Titan
Iovance downgraded to Neutral at UBS related to Amtagvi concerns - MSN
Q2 2025 Iovance Biotherapeutics Inc Earnings Call Transcript - GuruFocus
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Iovance Biotherapeutics (NASDAQ:IOVA) Rating Increased to Hold at Truist Financial - MarketBeat
Is It Time To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge - Yahoo Finance
Advanced Cell-based Therapy Booming the Success for Healthcare Sector - Sahm
Is Iovance Biotherapeutics (IOVA) Offering A Compelling Opportunity After Recent Price Swings? - sahmcapital.com
IOVA Technical Analysis | Trend, Signals & Chart Patterns | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference - simplywall.st
Iovance Biotherapeutics Inc (IOVA) 財務データ
収益
当期純利益
現金流量
EPS
Iovance Biotherapeutics Inc (IOVA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
31,246 |
0 |
148,477 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
39,059 |
0 |
257,590 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
31,246 |
0 |
142,394 |
| Vogt Frederick G | Interim CEO & General Counsel |
Mar 02 '26 |
Option Exercise |
0.00 |
52,087 |
0 |
516,609 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
12,307 |
0 |
118,051 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
5,470 |
0 |
221,329 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
12,697 |
0 |
124,353 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Feb 24 '26 |
Option Exercise |
0.00 |
120,000 |
0 |
173,546 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Feb 10 '26 |
Option Exercise |
0.00 |
39,996 |
0 |
69,996 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Dec 02 '25 |
Option Exercise |
0.00 |
3,906 |
0 |
113,640 |
2.68%
0.34%
大文字化:
|
ボリューム (24 時間):